Abbvie’s Migraine Medication Authorised for NHS Use

Abbvie’s migraine treatment has received a final draft guidance from the National Institute for Health and Care Excellence for NHS use in over 18-year-olds.  

The treatment ‘Aquipta’ can be used for the management of both infrequent and chronic migraines. In the final draft, the treatment is advised for those who experience a minimum of 4 migraines per month and have tried at least 3 other treatment options.  

Aquipta was granted commercialsiation authorisation after successful results from two late-stage studies conducted in September of last year.  

The medication will be made available for the NHS in May 2024, priced at just over £460 for 28 tablets.  

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.